TG Therapeutics
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| TG Therapeutics (TGTX) | 9.57B | 94.54 | 16.73 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 2.2% above Morningstar's fair value estimate.
Fair value
TG Therapeutics Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% premium over our quantitative fair value estimate of $61.92 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The firm's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 6.6% lies in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.
On a different note, the firm's balance sheet is reassuring. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. The firm's EBITDA/interest coverage ratio of 3.7, a core component of leverage, ranks in the bottom 30% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:20 · For reference only, not investment advice and not tailored to your situation.
TG Therapeutics discussion 0 comments